Àá½Ã¸¸ ±â´Ù·Á ÁÖ¼¼¿ä. ·ÎµùÁßÀÔ´Ï´Ù.

±¹¼ÒÁøÇ༺ Á÷Àå¾Ï¿¡¼­ ¼ö¼ú Àü ¹æ»ç¼± ¹× Ç×¾ÏÈ­ÇÐ µ¿½Ã¿ä¹ýÀÇ È¿°ú Efficacy of a Preoperative Concurrent Chemoradiotherapy for the Locally Advanced Unresectable Rectal Cancer

´ëÇѹæ»ç¼±Á¾¾çÇÐȸÁö 2000³â 18±Ç 4È£ p.293 ~ 299
¼Ò¼Ó »ó¼¼Á¤º¸
Á¶ÀçÈ£/Jae Ho Cho ¼ºÁø½Ç/±Ý±ââ/±è±Í¾ð/¼­Ã¢¿Á/³ëÀç°æ/Á¤Çöö/¹ÎÁø½Ä/±è³²±Ô/Jinsil Seong/Ki Chang Keum/Gwi Eon Kim/Chang Ok Suh/Jae Kyung Roh/Hyun Cheol Chung/Jin Sik Min/Nam Kyu Kim

Abstract

¸ñ Àû : Á÷Àå¾Ï¿¡¼­ ¿ÏÄ¡¸¦ ±â´ëÇÒ ¼ö ÀÖ´Â Ä¡·á´Â ¼ö¼ú¿ä¹ýÀÌ´Ù. ÁøÇ༺ º´º¯À¸·Î¼­ ±ÙÄ¡ÀýÁ¦°¡ ºÒ°¡´ÉÇÑ °æ¿ì¿¡ À־´Â ¼ö¼ú Àü º¸Á¶¿ä¹ýÀ» ÅëÇØ ÀýÁ¦¿¬ÀÌ À½¼ºÀÎ ±ÙÄ¡ÀýÁ¦À²À» ³ôÀÌ°íÀÚ ÇÏ´Â ³ë·ÂÀÌ ½ÃµµµÇ°í ÀÖ´Ù. ÀÌ¿¡ ÀúÀÚµéÀº ¼ö¼ú Àü ¹æ»ç¼± ¹× Ç×¾ÏÈ­ÇÐ
µ¿½Ã¿ä¹ýÀ¸·Î ±ÙÄ¡ ÀýÁ¦À²À» ³ô¿© Ä¡·á¼ºÀûÀ» Çâ»ó½ÃÅ°±â À§ÇÏ¿© ÀüÇâÀû ÀÓ»ó ¿¬±¸¸¦ ½ÃÇàÇÏ¿´´Ù.
´ë»ó ¹× ¹æ¹ý : 1995³â 1¿ùºÎÅÍ 1998³â 6¿ù±îÁö ±¹¼ÒÀûÀ¸·Î ÁøÇàµÈ Á÷Àå¾ÏÀ¸·Î ³»¿øÇÏ¿© ¼ö¼úÀü º´±â°áÁ¤ °Ë»ç¸¦ ÅëÇÏ¿© ±ÙÄ¡Àû ÀýÁ¦°¡ ºÒ°¡´ÉÇÏ´Ù°í ÆÇ´ÜµÈ 37¸íÀÇ È¯ÀÚ°¡ º» ¿¬±¸¿¡ Æ÷ÇԵǾú´Ù. ¼ö¼úÀü º´±â°áÁ¤Àº Á÷Àå¼öÁö°Ë»ç, °æÁ÷ÀåÃÊÀ½ÆÄ, ÄÄÇ»ÅÍ´ÜÃþÃÔ¿µ,
ÀÚ±â°ø¸í¿µ»ó µîÀ» ÀÌ¿ëÇÏ¿´´Ù. ¹æ»ç¼± Ä¡·á´Â 3 ¹® ³»Áö 4 ¹® Á¶»ç½ÄÀ¸·Î ÃÑ 45¡­50.4 Gy¸¦ ½ÃÇàÇÏ¿´À¸¸ç, ¹æ»ç¼± Ä¡·á ù° ÁÖ¿Í ´Ù¼¸Â° ÁÖ¿¡ Ç×¾ÏÈ­Çпä¹ý(5-Fluorouracil, 370¡­450 mg/m2, IV bolus, 5 days; Leucovorin 20 mg/m2, IV
bolus, 5
days)ÀÌ µ¿½Ã¿¡ Åõ¿©µÇ¾ú´Ù. ¹æ»ç¼± Ä¡·á ÈÄ 4¡­6ÁÖ ÈÄ¿¡ ±ÙÄ¡ÀûÀýÁ¦¼úÀ» ½ÃÇàÇÏ¿´´Ù. Àüü 37¸íÀÇ È¯ÀÚ Áß 31¸í¿¡¼­ °èȹµÈ ¹æ»ç¼± ¹× Ç×¾ÏÈ­ÇÐ µ¿½Ã¿ä¹ý ÈÄ ±ÙÄ¡Àû ¼ö¼úÀÌ ½ÃÇàµÇ¾ú°í, ³ª¸ÓÁö 6¸íÀº ȯÀÚ ÀÌÇغÎÁ·À¸·Î Ä¡·á°¡ Áß´Ü µÈ °æ¿ì 4¿¹, Ä¡·áÁß ÁøÇ༺
º´º¯(Perforation)À¸·Î ÀÀ±Þ¼ö¼úÀ» ½ÃÇàÇÑ ÈÄ ¹æ»ç¼± ´Üµ¶Ä¡·á¸¦ ÇÑ °æ¿ì 1¿¹, ±×¸®°í 1¿¹¿¡¼­´Â ¹æ»ç¼± ¹× Ç×¾ÏÈ­ÇÐ µ¿½Ã¿ä¹ýÀ» ½ÃÇà ÈÄ ¼ö¼úÇϱâ Àü¿¡ ÆóÀüÀÌ°¡ ¹ß°ßµÇ¾î Àü½ÅÇ×¾ÏÈ­ÇÐ ¿ä¹ý¸¸À» ½ÃÇàÇÏ¿´´Ù.
°á °ú : °èȹµÈ Ä¡·á°¡ ½ÃÇàµÈ ȯÀÚ Áß 94% (29/31)¿¡¼­ ÀýÁ¦¿¬ À½¼ºÀÎ ¿ÏÀü±ÙÄ¡ÀýÁ¦°¡ °¡´ÉÇÏ¿´À¸¸ç, º´¸®Àû ¿ÏÀü°üÇØÀ²Àº 6% (2/31), ÀÓ»óÀû ¿ÏÀü°üÇØÀ²Àº 23% (7/31)À̾ú´Ù. ¼ö¼ú Àü º´±â °¨¼ÒÀ²Àº 68%¿¡¼­ °üÂûµÇ¾ú´Ù. ¼ö¼úÀº 2¿¹¿¡¼­ ±¹¼Ò ÀýÁ¦¼ú, 14¿¹¿¡¼­
ÀúÀ§Àü¹æÀýÁ¦¼ú, 8¿¹¿¡¼­ º¹È¸À½ºÎ ÀýÁ¦¼ú, 4¿¹¿¡¼­ ÇÏÆ®¸¸¾¾ ÀýÁ¦¼ú, 3¿¹¿¡¼­ ºÎºÐ ³»¿ëÁ¦°Å¼úÀ» ½ÃÇàµÇ¾ú´Ù. Ä¡·á¿Í ¿¬°üµÈ ±Þ¼º µ¶¼ºÀ¸·Î´Â Grade III & IVÀÇ ¹éÇ÷±¸ °¨¼ÒÁõ °¢°¢ 4¿¹(13%), 2¿¹(6%)¸¦ Á¦¿ÜÇÏ°í´Â ´ëºÎºÐ °æ¹ÌÇÏ¿´´Ù.
°á ·Ð : ±¹¼ÒÀûÀ¸·Î ÁøÇàµÇ¾î ±ÙÄ¡Àû ÀýÁ¦°¡ ¾î·Á¿î Á÷Àå¾Ï¿¡¼­ °èȹµÈ ¼ö¼ú Àü ¹æ»ç¼± ¹× Ç×¾ÏÈ­ÇÐ µ¿½Ã¿ä¹ýÀ» ÅëÇؼ­ ¼ö¼ú ÈÄ º´±â °¨¼Ò(68%)¿Í ³ôÀº ¿ÏÀü±ÙÄ¡ÀýÁ¦À²(94%)À» ¾òÀ» ¼ö ÀÖ¾ú´Ù. Ä¡·á¿¡ µû¸¥ µ¶¼ºµµ ´ëºÎºÐ °æ¹ÌÇÏ¿© ÁÁÀº ¼øÀÀµµ¸¦ º¸¿´´Ù. ³ª¾Æ°¡
ÀÌ·¯ÇÑ
Ä¡·á¸¦ ÅëÇØ ¾ò¾îÁö´Â ±¹¼Ò Á¦¾îÀ²°ú Àüü »ýÁ¸À²¿¡ ´ëÇؼ­´Â ÇâÈÄ ÃßÀû °üÂûÀ» ÅëÇØ ºÐ¼®ÇØ ³ª°¥ ¿¹Á¤ÀÌ´Ù.

Purpose : We conducted a prospective non-randomized clinical study to evaluate the efficacy and toxicity of the preoperative concurrent chemoradiotherapy for locally advanced unresectable rectal cancer.
Materials and Methods : Between January 1995 and June 1998, 37 consecutive patients with locally unresectable advanced rectal cancer were entered into the study. With 3- or 4- fields techniuqe, a total of 45 Gy radiation was delivered on whole
pelvis,
followed by 5.4 Gy boost to the primary tumor in some cases. Chemotherapy was done at the first and fifth week of radiation with bolus i.v. 5-Fluorouracil (FU) 370¡­450 mg/m2, days 1¡­5, plus Leucovorin 20 mg/m2, days 1¡­5.
Of
37
patients, 6 patients did not receive all planned treatment course (refusal in 4, disease progression in 1, metastasis to lung in 1). Surgical resection was undergone 4¡­6 weeks after preoperative concurrent chemoradiotherapy.
Results : Complete resection rate with negative margins was 94% (29/31). Complete response was seen in 7 patients (23%) clinically and 2 patients (6%) pathologically. Down staging of tumor occured in 21 patients (68%). Treatment related toxicity
was
minimal except grade III & IV leukopenia in 2 patients, respectively.
Conclusion : Preoperative concurrent chemoradiotherapy in locally advanced rectal cancer was effective in inducing down staging and complete resection rate. Treatment related toxicity was minimal. Further follow up is on-going to determine long
term
survival following this treatment.

Å°¿öµå

Preoperative chemoradiotherapy; Rectal cancer;

¿ø¹® ¹× ¸µÅ©¾Æ¿ô Á¤º¸

   

µîÀçÀú³Î Á¤º¸

KCI
KoreaMed
KAMS